Coherus Biosciences | CHRS - Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Akebia Therapeutics USD 265.42M 199K 2025-12
ALKERMES USD 167.54M 1.08M 2026-06
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Amarin USD 20.81M 13K 2025-12
Amgen USD 541M 1000K 2026-06
Baxter International USD 517M 549K 2026-06
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Fujifilm JPY 1.21B 33K 2026-03
Gilead Sciences USD 1.24B 1000K 2026-06
Ironwood Pharmaceuticals USD 160K 0 2024-12
Merck USD 2.47B 4.93M 2026-03
Myriad Genetics USD 93.5M 400K 2025-12
Pacira USD 39.82M 512K 2026-06
Perrigo USD 138.1M 500K 2026-03
Pfizer USD 5.7B 0 2026-06
PTC Therapeutics USD 82.88M 1.41M 2026-03
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 105.62M 53K 2026-06
Teva Pharmaceutical Industries USD 1.16B 1000K 2026-06
Vertex Pharmaceuticals USD 253.3M 900K 2026-06
Xencor USD 74.33M 265K 2026-06
Zoetis USD 414.15M 6.19M 2026-06